Tom 12, Nr 4 (2017)
Opis przypadku
Opublikowany online: 2017-09-19
Wyświetlenia strony
855
Wyświetlenia/pobrania artykułu
4800
Skuteczna terapia lewosimendanem u chorego z zaostrzeniem przewlekłej niewydolności serca z obniżoną frakcją wyrzutową lewej komory
DOI: 10.5603/FC.2017.0070
Folia Cardiologica 2017;12(4):378-385.
Streszczenie
Mężczyzna w wieku 62 lat został przyjęty z powodu zaostrzenia objawów przewlekłej niewydolności serca do IV klasy według New York Heart Association. Mimo zastosowania standardowej farmakoterapii ostrej niewydolności serca u chorego doszło do objawów hipoperfuzji narządowej z następczą oligurią, do bezmoczu włącznie. Pacjent został zakwalifikowany do leczenia lewosimendanem, dzięki czemu w kolejnych dobach uzyskano stabilizację stanu klinicznego chorego. Na podstawie przypadku klinicznego w artykule przedstawiono aktualny stan wiedzy na temat zastosowania lewosimendanu w ostrej niewydolności serca.
Słowa kluczowe: ostra niewydolność sercafarmakoterapialewosimendan
Referencje
- Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
- Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009; 53(7): 557–573.
- Solomon SD, Dobson J, Pocock S, et al. Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007; 116(13): 1482–1487.
- Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006; 27(22): 2725–2736.
- Landoni G, Biondi-Zoccai G, Greco M. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012; 40(2): 634–646.
- Rozentryt P. Zastój narządowy w niewydolności serca. Terapia. 2016; 9(2).
- SIMDAX® monografia produktu. Orion Pharma 2015.
- Follath F, Cleland JGF, Just H, et al. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002; 360(9328): 196–202.
- Moiseyev VS, Põder P, Andrejevs N, et al. RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002; 23(18): 1422–1432.
- Follath F, Yilmaz MB, Delgado JF, et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med. 2011; 37(4): 619–626.
- Pollesello P, Parissis J, Kivikko M, et al. Levosimendan meta-analyses: is there a pattern in the effect on mortality? Int J Cardiol. 2016; 209: 77–83.
- Cleland JGF, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail. 2004; 6(4): 501–508.
- Cleland JGF, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006; 8(1): 105–110.
- Ribeiro RA, Rohde LE, Polanczyk CA. Levosimendan in acute decompensated heart failure: systematic review and meta-analysis. Arq Bras Cardiol. 2010; 95(2): 230–237.
- Delaney A, Bradford C, McCaffrey J, et al. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. Int J Cardiol. 2010; 138(3): 281–289.
- Gong B, Li Z, Yat Wong PC. Levosimendan treatment for heart failure: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2015; 29(6): 1415–1425.
- Fedele F, D'Ambrosi A, Bruno N, et al. Cost-effectiveness of levosimendan in patients with acute heart failure. J Cardiovasc Pharmacol. 2011; 58(4): 363–366.
- Fedele F, Karason K, Matskeplishvili S. Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan. Eur Heart J Suppl. 2017; 19(Suppl C): C22–C28.
- Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013; 41(10): 2328–2335.
- Farmakis D, Alvarez J, Gal TB, et al. Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. Int J Cardiol. 2016; 222: 303–312.
- Nikolaou M, Parissis J, Yilmaz MB, et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J. 2013; 34(10): 742–749.
- Simdax® — Charakterystyka Produktu Leczniczego.
- Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused 4pdate of the 2013 ACCF/AHA guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017 [Epub ahead of print].
- Delgado JF, Oliva F, Reinecke A. The inodilator levosimendan in repetitive doses in the treatment of advanced heart failure. Eur Heart J Suppl. 2017; 19(Suppl C): C8–C14.
- Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003; 107(1): 81–86.
